News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn’s Boon Loo Talks to Technical.ly Philly about his Experience in Academic Entrepreneurship
Penn Engineering’s Boon Thau Loo, PhD, Senior Associate Dean for Education and Global Initiatives, was featured in Technical.ly Philly for his deep personal experiences with academic entrepreneurship.
Penn Leads NSF Sponsored AIRFoundry to Revolutionize RNA Research, Leveraging AI to Further Optimize and Innovate
It is an $18-million initiative focused on advancing RNA research through AI-driven innovation and advanced manufacturing techniques.
The Pennsylvania Gazette Shines the Spotlight on the Past Decade of President’s Engagement and Innovation Prize Winners
PCI supports the President’s Innovation Prize.
Penn spinout Linnaeus Therapeutics secures an additional $1.6M in Funding
Penn spinout Linnaeus Therapeutics has raised another $1.6 million in financing, bringing its cumulative funding total to over $13 million since 2018.
Penn Robotics Startup Sahay AI Aims to Make Railroads Safer
Sahay AI is focused on transforming railway inspections through innovative AI-powered solutions.
Penn Spinout Heirloom Carbon Technologies Secures $475 Million Commitment for North America’s Second Direct Air Capture Facility in Louisiana
Penn spinout Heirloom Carbon Technologies plans to invest $475 million to build its second Direct Air Capture (DAC) facility in North America, located at the Port of Caddo-Bossier in Louisiana.
Exyn Technologies and Stitch3D Announce Partnership; Exyn Advances AI Aerial Autonomy Technology to Overcome Dust in Underground Mines
The goal of the collaboration is to to host, manage, view, process and share point cloud data securely directly on the web.
iECURE included on list of Fierce Biotech’s 2024 Fierce 15
iECURE was recognized for its innovative approach to treating rare childhood diseases by developing therapies that correct gene function directly inside the body.
Penn Spinout Interius BioTherapeutics Raises Additional $67M and doses first patient
The company’s approach focuses on creating cancer-fighting cells directly inside the body, potentially bypassing the need for external cell manipulation and chemotherapy.
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
Carisma has expanded its collaboration with Moderna to develop two chimeric antigen receptor macrophage (CAR-M) targets for autoimmune disease treatment.